{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:13:54Z","timestamp":1788164034802,"version":"build-2803163510"},"reference-count":51,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Infectious complications are increasingly recognized as a crucial aspect of the clinical management of patients with Myelofibrosis. Infection susceptibility is multifactorial and reflects the interplay between disease\u2010related immune dysregulation, treatment\u2010associated immunomodulation, and patient\u2010specific factors such as age, comorbidities, and prior therapies. Myelofibrosis is characterized by a chronic inflammatory state and impaired innate and adaptive immunity, including dysfunction of natural killer cells, dendritic cells, and T lymphocytes. The introduction of JAKis has significantly improved disease outcomes, while these agents may further modulate immune responses through inhibition of the JAK\u2013STAT pathway. Evidence from clinical trials and real\u2010world studies indicates that bacterial infections are common, while viral reactivations, particularly herpes zoster, represent a consistent complication of JAKi therapy. Opportunistic infections are less frequent but clinically relevant. In our view, infection risk in myelofibrosis should be considered an intrinsic component of disease biology and treatment. A risk\u2010adapted approach integrating baseline assessment, vaccination, and close clinical monitoring is warranted. Future efforts should focus on biomarker\u2010driven risk stratification and tailored preventive strategies to optimize outcomes in patients receiving JAKis.<\/jats:p>","DOI":"10.1111\/ejh.70302","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T07:16:58Z","timestamp":1788160618000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Immune Dysfunction to Clinical Risk: Infections in Myelofibrosis"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9280-2023","authenticated-orcid":false,"given":"Laura","family":"De Fazio","sequence":"first","affiliation":[{"name":"Division of Hematology\u2010Oncology Azienda Universitaria Ospedaliera Renato Dulbecco  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Simio","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Azienda Universitaria Ospedaliera Renato Dulbecco  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-4406","authenticated-orcid":false,"given":"Matteo","family":"Molica","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Azienda Universitaria Ospedaliera Renato Dulbecco  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7258-475X","authenticated-orcid":false,"given":"Marco","family":"Rossi","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Azienda Universitaria Ospedaliera Renato Dulbecco  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"issue":"16","key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2023022415","article-title":"How I Individualize Selection of JAKis for Patients With Myelofibrosis","volume":"145","author":"Masarova L.","year":"2025","journal-title":"Blood"},{"issue":"4","key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3324\/haematol.2025.288654","article-title":"JAK Inhibitor Selection in Challenging Scenarios of Myelofibrosis: A Review","volume":"111","author":"Vachhani P.","year":"2026","journal-title":"Haematologica"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010021\u201000526\u2010z"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750346"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1345402"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201003\u2010484642"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201014\u20103198"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419\u2010026\u201008610\u20107"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13373"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd5318"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.11.032"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1688323"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2509"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.035"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.235"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756\u20100500\u20105\u2010552"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.104"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12\u20101604"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010019\u20103922\u20106"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2017.1390248"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010020\u201005703\u20102"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020578"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24572"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017423"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010023\u201001471\u2010z"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24976"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2511564"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16174"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010017\u20100527\u20107"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(17)30027\u20103"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70005"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16729"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2550924"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010022\u201010777\u2010w"},{"key":"e_1_2_11_41_1","unstructured":"Administration. U.S. Food and Drug \u201cJakafi (Ruxolitinib) Prescribing Information \u201d2025."},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01757"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.4899"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(18)30601\u20107"},{"key":"e_1_2_11_45_1","unstructured":"Network. National Comprehensive Cancer \u201cMyeloproliferative Neoplasms \u2014 Supportive Care (MPN\u2010F) \u201dNCCN Guidelines Version 1 2026."},{"key":"e_1_2_11_46_1","unstructured":"\u201cPrevention and Treatment of Cancer\u2010Related Infections \u201dNCCN Guidelines Version 1 2026."},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101610"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113132"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01186"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S121683"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27658"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100970\u20102"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70302","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70302","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T07:17:00Z","timestamp":1788160620000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":51,"alternative-id":["10.1111\/ejh.70302"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70302","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"2026-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ejh.70302"}}